These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2340511)

  • 1. Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes.
    Fan D; Bucana CD; O'Brian CA; Zwelling LA; Seid C; Fidler IJ
    Cancer Res; 1990 Jun; 50(12):3619-26. PubMed ID: 2340511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming murine tumor cell resistance to vinblastine by presentation of the drug in multilamellar liposomes consisting of phosphatidylcholine and phosphatidylserine.
    Seid CA; Fidler IJ; Clyne RK; Earnest LE; Fan D
    Sel Cancer Ther; 1991; 7(3):103-12. PubMed ID: 1771296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Goldenberg GJ; Wang H; Blair GW
    Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of doxorubicin resistance by valinomycin (NSC 122023) and liposomal valinomycin in Chinese hamster ovary cells.
    Daoud SS; Juliano RL
    Cancer Res; 1989 May; 49(10):2661-7. PubMed ID: 2713850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.
    Ramu N; Ramu A; Cole DE; Balis FM; Poplack DG; Pollard HB
    Isr J Med Sci; 1988; 24(9-10):477-82. PubMed ID: 2974448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-dependent differences in response of the UV-2237 murine fibrosarcoma to systemic therapy with adriamycin.
    Staroselsky AN; Fan D; O'Brian CA; Bucana CD; Gupta KP; Fidler IJ
    Cancer Res; 1990 Dec; 50(24):7775-80. PubMed ID: 2253220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
    Lopez-Barcons LA; Polo D; Llorens A; Reig F; Fabra A
    Oncol Rep; 2005 Nov; 14(5):1337-43. PubMed ID: 16211306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA breakage, cytotoxicity, drug accumulation and retention in two human ovarian tumor cell lines AZ224 and AZ364 treated with adriamycin, modulated by verapamil.
    Delvaeye M; Verovski V; De Neve W; Storme G
    Anticancer Res; 1993; 13(5A):1533-8. PubMed ID: 8239532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
    Politi PM; Sinha BK
    Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
    Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced therapeutic effect against liver W256 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery.
    Zou Y; Yamagishi M; Horikoshi I; Ueno M; Gu X; Perez-Soler R
    Cancer Res; 1993 Jul; 53(13):3046-51. PubMed ID: 8319211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
    Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
    Mayer LD; Dougherty G; Harasym TO; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentapeptide YIGSR-mediated HT-1080 fibrosarcoma cells targeting of adriamycin encapsulated in sterically stabilized liposomes.
    Lopez-Barcons LA; Polo D; Reig F; Fabra A
    J Biomed Mater Res A; 2004 Apr; 69(1):155-63. PubMed ID: 14999763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
    Parr MJ; Masin D; Cullis PR; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
    Tapiero H; Nguyen-Ba G; Lampidis TJ
    Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
    Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
    Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells.
    Astier A; Doat B; Ferrer MJ; Benoit G; Fleury J; Rolland A; Leverge R
    Cancer Res; 1988 Apr; 48(7):1835-41. PubMed ID: 2894892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization in vitro and in vivo of progressively adriamycin-resistant B16-BL6 mouse melanoma cells.
    Ganapathi R; Grabowski D; Schmidt H; Bell D; Melia M
    Cancer Res; 1987 Jul; 47(13):3464-8. PubMed ID: 2884031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.